Stacie Hudgens MSc, Chief Executive Officer, Strategic Lead Regulatory and Access, has a manuscript published in The Lancet this month, entitled ‘Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial’. This is a paper focused on understanding health-related quality of life in an ovarian maintenance clinical trial.
To read, please click here.
To see more about Stacie, please click here.